Doctors have been treating cancer the same way for decades: give a drug, wait for it to stop working, then switch.
Turns out that "wait" might be the most expensive word in oncology.
A new study says the smarter move is to switch treatments while the tumor is still shrinking — before it gets the chance to fight back.
Cancer cells mutate randomly as they divide.
Most mutations do nothing.
But every so often, one lets a cell survive the exact drug trying to kill it.
That single cell keeps multiplying.
Months later, it is the tumor.
Dr. Robert Noble, a mathematician at City St George's, University of London, calls this the hidden cost of standard care: doctors usually wait for scans to confirm the cancer is regrowing before changing drugs.
By then, resistant cells have had plenty of time to take over.
Noble's team borrowed math models built for a totally different problem — how species evolve under climate pressure.
Swap "climate" for "chemo," and the same logic applies.
Their models suggest switching therapies early, before resistance takes hold, beats waiting every time.
It's the same evolutionary trick already used against:
Cancer, Noble argues, should be no different.
There's already a real-world hint this works. A prostate cancer trial testing this evolutionary logic saw all standard-care patients relapse — while several patients on the adaptive approach stayed stable for over four years, using less than half the drug dose.
Here's the twist that could matter most.
Two-drug switching, even perfectly timed, mostly works on small tumors.
Noble's models say three or more sequential therapies could take down larger ones too — each drug forcing the cancer to solve a different problem before it can adapt.
Three small trials are already running, in soft-tissue, prostate, and breast cancer.
The results are still math on a screen, not proof in patients.
But if the models hold up, the biggest shift in cancer care might not be a new drug at all.
It might just be timing.
That's all for now!
